文献速递淋巴瘤

分子高级别B细胞淋巴瘤:定义需不同治疗方法的预后不良组

Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.
PubMed 文献 · J Clin Oncol · 2018-12-03

研究基于928例DLBCL患者的基因表达分类器定义分子高级别(MHG)组,占9%,其特征为增殖表型且与中心母细胞相关。MHG组R-CHOP后36个月无进展生存率为37%,其他组为72%,且硼替佐米可能带来获益。MHG定义了一个生物学一致的高级别B细胞淋巴瘤组,使预后不良的双打击组规模 effectively 翻倍。

要点

  • MHG组占DLBCL的9%(83/928),其中75例属生发中心B细胞样亚型。
  • MHG组36个月无进展生存率为37%(95%CI 24%-55%),其他组为72%(95%CI 68%-77%)。
  • 缺乏MHG特征的双打击淋巴瘤未见预后差于其他生发中心B细胞样病例。

核心结论

  • MHG定义了一个具有独特分子特征和临床结局的生物学一致的高级别B细胞淋巴瘤组,使预后不良的双打击组规模 effectively 翻倍。
  • MHG患者可能从强化化疗或新型靶向治疗中获益。

研究设计与样本

  • 研究应用基于基因表达的分类器对来自一项临床试验的928例DLBCL患者进行分组,该试验探讨在标准R-CHOP方案基础上加用硼替佐米。
  • 对400例患者进行了70个基因的靶向测序,并利用基因表达特征数据库探索分子病理学。
  • 研究结果在独立数据集中得到验证。

主要发现

  • MHG组包含83例患者(9%),其中75例属于细胞起源的生发中心B细胞样组。
  • MYC重排组和双打击组在MHG中强烈过代表,但仅占MHG总数的一半。
  • 基因表达分析显示增殖表型,与中心母细胞相关。
  • MHG组R-CHOP后36个月无进展生存率为37%(95%CI 24%-55%),其他组为72%(95%CI 68%-77%)。
  • 治疗效应分析提示硼替佐米可能具有正面效应。

关键数值与推荐

  • MHG组:83例(9%),其中75例为生发中心B细胞样。
  • MHG组36个月无进展生存率37%(95%CI 24%-55%),其他组72%(95%CI 68%-77%)。

临床怎么用

  • MHG患者可能从强化化疗或新型靶向治疗中获益(作者结论)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Biologic heterogeneity is a feature of diffuse large B-cell lymphoma (DLBCL), and the existence of a subgroup with poor prognosis and phenotypic proximity to Burkitt lymphoma is well known. Conventional cytogenetics identifies some patients with rearrangements of MYC and BCL2 and/or BCL6 (double-hit lymphomas) who are increasingly treated with more intensive chemotherapy, but a more biologically coherent and clinically useful definition of this group is required. PATIENTS AND METHODS: We defined a molecular high-grade (MHG) group by applying a gene expression-based classifier to 928 patients with DLBCL from a clinical trial that investigated the addition of bortezomib to standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. The prognostic significance of MHG was compared with existing biomarkers. We performed targeted sequencing of 70 genes in 400 patients and explored molecular pathology using gene expression signature databases. Findings were validated in an independent data set. RESULTS: The MHG group comprised 83 patients (9%), with 75 in the cell-of-origin germinal center B-cell-like group. MYC rearranged and double-hit groups were strongly over-represented in MHG but comprised only one half of the total. Gene expression analysis revealed a proliferative phenotype with a relationship to centroblasts. Progression-free survival rate at 36 months after R-CHOP in the MHG group was 37% (95% CI, 24% to 55%) compared with 72% (95% CI, 68% to 77%) for others, and an analysis of treatment effects suggested a possible positive effect of bortezomib. Double-hit lymphomas lacking the MHG signature showed no evidence of worse outcome than other germinal center B-cell-like cases. CONCLUSION: MHG defines a biologically coherent high-grade B-cell lymphoma group with distinct molecular features and clinical outcomes that effectively doubles the size of the poor-prognosis, double-hit group. Patients with MHG may benefit from intensified chemotherapy or novel targeted therapies.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sha C, Barrans S, Cucco F, et al. Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy. J Clin Oncol. 2018. PMID: 30523719. doi:10.1200/JCO.18.01314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。